Pharvaris (PHVS) EBITDA (2020 - 2026)
Pharvaris' (PHVS) quarterly EBITDA came in at -$51.8 million in Q1 2026, up 100.0% YoY from -$25.9 million in Q1 2025, and up 74.37% on a QoQ basis from -$202.2 million in Q4 2025.
Pharvaris (PHVS) EBITDA (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of EBITDA data on file, last reported at -$51.8 million in Q1 2026.
- Quarterly EBITDA rose 100.0% year-over-year to -$51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$305.3 million (up 100.0% YoY) and the FY2025 annual result came in at -$196.3 million, down 36.96% from the prior year.
- EBITDA rose to -$51.8 million in Q1 2026, from -$202.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$46.37 in Q3 2025 to a low of -$44375124102.2 billion in Q1 2025.
- A 5-year average of -$2610304572.9 billion and a median of -$51.3 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2025 — EBITDA plunged 144276773.01% — and 2026, when it surged 100.0%.
- Tracing PHVS's EBITDA over 5 years: stood at -$77.2 million in 2022, then plunged by 332973.03% to -$257.1 billion in 2023, then jumped by 99.94% to -$141.5 million in 2024, then plunged by 42.92% to -$202.2 million in 2025, then jumped by 74.37% to -$51.8 million in 2026.
- The last three EBITDA figures came in at -$51.8 million (Q1 2026), -$202.2 million (Q4 2025), and -$46.37 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | -54.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.91 Mn |
| Mar 31, 2026 | -51.83 Mn |
| Dec 31, 2025 | -202.21 Mn |
| Sep 30, 2025 | -46.37 |
| Jun 30, 2025 | -51.25 Mn |
| Mar 31, 2025 | -44,375,124,102.22 Bn |
| Dec 31, 2024 | -141.48 Mn |
| Sep 30, 2024 | -41.63 Mn |
| Jun 30, 2024 | -31.94 Mn |
| Mar 31, 2024 | -30,756.92 Bn |
| Dec 31, 2023 | -257.08 Bn |
| Sep 30, 2023 | -25.53 Mn |
| Jun 30, 2023 | -23.74 Mn |
| Mar 31, 2023 | -22,621.78 Bn |
| Dec 31, 2022 | -77.19 Mn |
| Sep 30, 2022 | -22.57 Mn |
| Jun 30, 2022 | -10.54 Mn |
| Mar 31, 2022 | -21.75 Mn |
| Dec 31, 2021 | -48.80 Mn |
| Sep 30, 2021 | -15.72 Mn |